ACRV
Acrivon Therapeutics, Inc. Common Stock
NASDAQ · Healthcare · Biotechnology · US
$2.13
+3.40%Next report
Analyst consensus
- Next report date
- Nov 12, 2026
- EPS estimate
- -$0.45
- Revenue estimate
- $504.3K
Latest reported
- Last report date
- Aug 12, 2026
- EPS actual
- -$0.43
- EPS estimate
- -$0.50
- Revenue actual
- —
- Revenue estimate
- $386.3K
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 8
- EPS misses (12Q)
- 0
- EPS in line (12Q)
- 2
- Avg surprise (4Q)
- +8.0%
- Revenue beats (12Q)
- —
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 12, 2026